Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized study to assess the effect on response rate of MabThera (rituximab) added to a standard chemotherapy, Bendamustine or Chlorambucil, in patients with Chronic Lymphocytic Leukemia.

Next Previous
X
Search
Trial Profile

A randomized study to assess the effect on response rate of MabThera (rituximab) added to a standard chemotherapy, Bendamustine or Chlorambucil, in patients with Chronic Lymphocytic Leukemia.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 16 Aug 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rituximab (Primary) ; Bendamustine; Chlorambucil
  • Indications Chronic lymphocytic leukaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms MaBLe; RiBECCA
  • Sponsors Roche

    • Most Recent Events

    • 17 Jun 2022 Results meta-analysis of randomized controlled trials from NCT0101006, NCT01886872, NCT01056510, and NCT03336333, presented at the 27th Congress of the European Haematology Association
    • 07 Jun 2022 Results of meta-analysis of randomized controlled trials ((NCT01010061), ALLIANCE (NCT01886872), MABLE (NCT01056510), and SEQUOIA (NCT03336333)) assessing relative efficacy of zanubrutinib compared with standard frontline treatments for chronic lymphocytic leukemia, presented at the 58th Annual Meeting of the American Society of Clinical Oncology.
    • 30 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top